Faculty Advisor

Buckholt, Michael Allan

Faculty Advisor

Rulfs, Jill

Abstract

Over the counter phytoestrogen supplements are used to treat menopausal symptoms purportedly, without the increased risk of breast cancer associated with estrogen replacement therapy. Extracts of one such supplement, Promensil, have been shown to reduce proliferation of the breast cancer cells T47D, but not to act through the estrogen receptor beta (ER-beta). Our hypothesis is that Promensil acts through estrogen receptor alpha (ER-alpha), which normally signals breast cancer cells to proliferate in response to estrogen. To test this, T47D cells were treated with Promensil alone, or Promensil with an ER-alpha antagonist. The data to date rejects our hypothesis that Promensil acts through ER-alpha.

Publisher

Worcester Polytechnic Institute

Date Accepted

April 2019

Major

Biology and Biotechnology

Project Type

Major Qualifying Project

Accessibility

Unrestricted

Advisor Department

Biology and Biotechnology

Share

COinS